The present study was aimed at identifying surface-membrane molecules involved in the regulation of human B-cell ontogeny. For this purpose, murine monoclonal antibodies (MoAbs) were generated against Pre-Alp, a pre-B acute lymphoblastic leukemia (ALL) cell line, and MoAb R34.34 was selected for further characterization. R34.34 recognized a molecule expressed on normal B-cell precursors (BCP) but not on mature B cells. The antibody also reacted with T lymphocytes, a subpopulation of monocytesfrom peripheral blood, and a subset of CD34+ cells. Immunoprecipitation analysis indicated that R34.34 recognizes an 80-kD molecular weight antigen. Antibody R34.34 was further found to be directed against an epitope interfering with binding of in-NTERLEUKIN-7 (IL-7) is a 25-kD glycoprotein involved in the regulation of lymphopoiesis.' Thus, human IL-7 has been described as a growth factor for normal and leukemic B-cell precursors (BCPS).'.~ However, IL-7 has been reported to deliver a growth-inhibitory signal to some BCPacute lymphoblastic leukemias (BCP-ALLs).',' In contrast to its effect on BCP, IL-7 is unable to stimulate the proliferation of mature B cells.' IL-7 is a costimulus for the proliferation of normal and leukemic thymocytes'.''.'' and for mature T cells, independently of IL-2.'2.'3 In addition, peripheral blood monocytes secrete IL-6 in response to IL-7.I4 A 75-to 80-kD human IL-7 receptor (IL-7R) has been cloned15 that belongs to the hematopoietic cytokine-receptor superfamily characterized by homology of extracellular binding domains. This IL-7R, assigned to CDw127 (5th International Conference on Human Leukocyte Differentiation Antigens, Boston, 1993), displays both high-and low-affinity for its ligand, the low-affinity receptor being the more represented. Binding of IL-7 to CDw127, which lacks a protein tyrosine kinase domain, induces tyrosine ph~sphorylation'~,'~ by recruiting the activity of p59 fyn tyrosine kinase.I8
terleukin-7 (IL-7) to Pre-Alp cells. Expression cloning from a
Pre-Alp cDNA library showed that R34.34 antigen is CDw127, the 75-to 80-kD IL-7 receptor. Proliferation of the B-lineage ALL cell lines Reh and Mieliki was inhibited by IL-7, and this effect was specifically reverted by MoAb R34.34. In addition, antibody R34.34 specifically inhibited IL-7-dependent proliferation of normal BCP, Pre-Alp cells, and peripheral T cells. These results imply that both inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. R34.34 antibody should be important for the analysis of signal transduction through CDw127. 0 1994 by The American Society of Hematology. ent centrifugation. T cells were subsequently enriched using immunomagnetic bead depletion (Dynal, Oslo, Norway) of B cells and monocytes. B cells were purified from tonsils after rosetting and immunomagnetic bead depletion of contaminant cells. CD34' hematopoietic progenitors were isolated from adult BM, as previously described.*' The following cell lines were used: Pre-Alp, Nalm6, Reh, and Mieliki (recently established in our laboratory; N. Renard et al, manuscript in preparation) (BCPs); RPMI 1788, Daudi, JY, and IM9 (mature B cells); and THP-l, HL60, KGI, and K562 (myeloid). All cell lines were cultured in RPMI 1640 (GIBCO, Grand Island, NY) supplemented with 10% vol/vol fetal calf serum (FCS; Flow Laboratories, Irvine, UK), 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin (hereafter known as complete medium). Cells were used for experiments during log phase of growth. All human tissues were obtained according to institutional guidelines.
Generation of MoAb R34.34. BALB/c mice (Iffa Credo, Les Oncins, France) were immunized with Pre-Alp, a t(1;19) pre-B leukemic cell line raised in our laboratory." Thus, 50 X lo6 Pre-Alp cells were intraperitoneally injected twice at 3-week intervals. Serum was found to react with Pre-Alp cells by immunofluorescence at a 1/800 dilution. At that point, 25 days after the second injection, mice were boosted with 250 X lo6 Pre-Alp cells and killed 3 days later.
A total of 50 X lo6 murine spleen cells was fused with NSI myeloma cells (ratio 5:l) with the use of polyethylene glycol 1500 (Boehringer, Mannheim, Germany) and cultured in complete medium supplemented with 20% voUvol FCS, hypoxanthine, azaserine, oxaloacetic acid, pyruvate, and insulin (OPI; Sigma, St Louis, MO). A total of 5 X lo3 intraperitoneal mouse macrophages was added per well as feeder cells. Hybridoma supernatants were harvested between day 14 and 17 and screened as described above. Selected PANDRAU-GARCIA ET AL hybridomas were cloned, until obtention of monoclonality as evaluated by statistical analysis, by limiting dilution at 0.5 cell/well in complete medium with OPI and 20% vol/vol FCS.
For ascites production, BALB/c mice were injected intraperitoneally with 0.5 mL pristane (Sigma). Eight days later, 2 X lo6 hybridoma cells were injected intraperitoneally, and ascites fluid was collected after 3 to 4 weeks. Ascites fluid was centrifuged at 3000s for 30 minutes to remove lipids and cellular debris. MoAb R34.34 was isolated from ascites fluid by high-pressure liquid chromatography with an anion-exchange column (DEAE 5PW; Waters Associates, Millipore Corp, Milford, MA). Ig isotype was determined by immunoassay with isotype-specific antimouse Ig antibodies coated on membranes (SangStat Medical Corp, Menlo Park, CA).
Zmmunoprecipifarion analysis. The 96-well round-bottomed polyvinyl chloride plates (Dynatech Laboratories, Chantilly, VA) were coated overnight at 4°C with 100 pg/mL mouse anti-lgG (Sigma). Subsequently, 5 pg of purified MoAb were incubated at 4°C for 4 hours. Alb-l (anti-CD10; Immunotech, Marseille, France) was used as positive and Immu 133.3 (anti-CD34; Immunotech) as negative control murine MoAbs. Saturation was performed for 2 hours with 1% vol/vol normal mouse serum in phosphate-buffered saline (PBS) containing 1 mmoVL NaN3. Pre-Alp cells, previously surface-labeled with 2 mCi Iz5I-Na (Amersham, Les Ulis, France) in the presence of 2 U/mL lactoperoxidase (Sigma) and H202 (Sigma), were lysed (4°C) with a lysis buffer (150 mmol/L NaCI; 50 mmoVL Tris, pH 7.6; 1% Nonidet P-40) containing 1 mmol/L phenylmethylsulfonyl fluoride, 0.5 mmoVL EDTA, 1 pmoVL leupeptine, and 1 pmoVL pepstatine A. The nuclei were pelleted, and 100 pL of the supernatant was incubated in each well overnight at 4°C. The immune complexes were harvested in glycine 0.1 moVL at room temperature and analyzed under reducing conditions by sodium dodecyl sulfate 12.5% polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography. cDNA library construction and expression cloning system. Poly (A)+ RNA was prepared from Pre-Alp cells. It was converted to double-strand cDNA by using Not I oligo(dT) primers and a cDNA synthesis kit (BRL, Gaithersburg, MD). The double strand was ligated with Bsrx I linkers and was size-fractionated by spin column (Spin 400; Clontech, Palo Alto, CA). The cDNAs longer than 400 bp were cloned into the Bsfx I-Nor I site of pMEIBs, an SV40-based mammalian expression vector." The cDNA library contained 5 X IO6 independent clones. Clones encoding R34.34 antigen were isolated from the library by incubating cDNA-transfected cos7 cells with R34.34, followed by selection (panning) of cells specifically adhering to plates coated with F(ab')* antimouse IgGI.*' Nucleotide sequence was determined by the dideoxy-chain termnation methodz4 using a Taq polymerase kit (Applied Biosystems, Roissy, France). All sequencing was performed on both strands using a 373A DNA sequencer (Applied Biosystems).
IL-7
Phenolype anulysis. Single-color surface immunofluorescence was performed according to standard techniques using IO pg/mL of MoAbs shown by fluorescein isothiocyanate (F1TC)-goat F(ab' )2 antimouse Ig (Bioan, Meudon, France) or by phycoerythrin (PE)-rabbit IgG anti-mouse Ig (Dako, Glostrup, Denmark). Double-color membrane fluorescence was performed on mononuclear blood cells by sequential incubation of the cells with unconjugated MoAbs. FITC-conjugated antimouse Ig, and MoAbs directly labeled with PE. MoAbs used were anti-CD3 (Immunotech), anti-CD14 (LeuM3). and anti-CD20 (Leul6) (Becton Dickinson, Mountain View, CA) to characterize T cells, monocytes, and B cells, respectively. Fluorescence was analyzed with a FACScan (Becton Dickinson, Sunnyvale, CA). Positive cells were determined by reference to nonspecific staining by control MoAbs of the same isotype but of unrelated specificity.
Proliferation assays. Pre-Alp and Reh cells were seeded in 96-well round-bottomed microtest tissue culture plates (Nunc, Roskilde, Denmark) at 5 X 10' cells/lOO pL in complete medium supplemented with 3% and 10% vol/vol FCS, respectively. T lymphocytes and Mieliki cells were seeded in similar conditions in complete medium supplemented with 10% FCS. Normal CDlO' sIg-BCP were cultured at lo4 cells/well in the presence of human stromal cells as de~cribed.~ Cells were incubated at 37°C and 5% COz, either in medium alone or in the presence of IL-7 (specific activity, 2.5 IO6 U/mg). In addition, T cells were cultured in the presence of IL-2 (specific activity, 5 X lo4 U/mg), obtained from Amgen (Thousand Oaks, CA), and IL-4 (specific activity, 1 X IO' U/mg), from ScheringPlough Research Institute (Kenilworth, NJ). Purified MoAb R34.34 was added to cultures at concentrations as indicated, and a murine MoAb of unrelated specificity was used as negative control.
After 4 to 6 days, cells were pulsed with 1 pCi methyl-'H-TdR (specific activity, 25 Ci/mmol; CEA, Saclay, France) for the last 8 hours of culture. 'H-TdR uptake was determined and expressed as counts per minute (cpm) ? standard deviation (SD) as measured in triplicate wells.
RESULTS

Generation of R34.34 MoAb and binding to various cell types.
To find novel surface molecules controlling BCP proliferation, mice were immunized with a human pre-B-ALL cell line (Pre-Alp), and resulting hybridomas were selected for their ability to modulate normal BCP DNA replication. Thus, supernatants from four hybridomas (R34.34, C64.24, D33.9, and E22.16) were found to inhibit fetal BCP proliferation in the presence of heterologous stromal cells (data not shown). Among them, antibody R34.34 showed the most potent effect and, therefore, was selected for further study. This antibody was found to be of IgGl isotype.
The binding of purified R34.34 antibody was first investigated by flow cytometry analysis on different cells. MoAb R34.34 reacted with leukemic BCP from Re-Alp (Fig IA) , Mieliki (Fig ID) , as well as Reh and Nalm6 cell lines (data not shown). In addition, the majority of CD10' sIgM-normal BCP from FBM ( Fig 1B) stained with the antibody. Reactivity was also observed on a small subpopulation of CD34' progenitor cells isolated from adult BM (Fig IC) . MoAb R34.34 is directed against the CDw127 IL-7 R. To characterize the antigen recognized by R34.34 antibody, Pre-Alp cells were surface-labeled using the lactoperoxidase method and '*'INa. As shown in Fig 2 (lane 3) , MoAb R34.34 immunoprecipitated a protein of about 80 kD. As a control, anti-CD10 MoAb Alb-l bound to a protein of 100 kD (Fig 2, lane 2) . In addition, no labeled proteins were detected using unrelated antibody (Fig 2, lane l) .
The molecular mass of R34.34 antigen and the pattern of expression described above suggested that R34.34 might recognize the 75-to 80-kD IL-7R.15 To formally identify R34.34 antigen. a cDNA library was established from PreAlp polyA mRNA using a mammalian expression vector. A 1.7-kb and a 1.4-kb cDNA were isolated after 4 panning cycles with MoAb R34.34. cos7 cells transfected with either I .7-kb or 1.4-kb cDNAs specifically bound R34.34 antibody (Fig 3) .
Nucleotide sequencing showed that the I .7-kb cDNA encoded the full-length IL-7R (CDw 127) previously reported." To avoid possible mutations of cDNA during serial passages in cos7 cells. a 1.7-kb EcoRI-Not I fragment was used as the hybridization probe to isolate another clone from the original library to permit complete sequence analysis. R34.34 antigen cDNA was found to be identical to the previously cloned human IL-7R apart from mutations at three nucleotide positions. Two of these mutations did not change the amino acid sequence. library. MoAb R34.34 did not bind to THP-I or RPM1 1788 cell lines (data not shown), indicating that the antibody does not cross-react with the low-affinity IL-7R that is present on these cell lines.I9 MoAb R34.34 reverts growth-inhibitory effect of IL-7 on B-lineage ALL cells. Because IL-7 has a potential to mediate growth inhibition in B-lineage ALL,'." it appeared to be of interest to examine whether this effect is influenced by MoAb R34.34. Proliferation of the Mieliki BCP-ALL cells was strongly inhibited by IL-7, with a maximum effect reached at 5 ng/mL (data not shown). As shown in Fig 4A, addition of MoAb R34.34 at the onset of culture resulted in reversal of this inhibitory activity of IL-7, whereas an unrelated control antibody had no effett. Maximum neutralization activity was reached at a concentration of MoAb R34.34 in the order of 3 pg/mL. However, MoAb R34.34 failed to completely revert the effect of IL-7, because 'H-TdR incorporation at the plateau of maximum antibody activity corresponded to approximately 63% of that observed in the absence of IL-7 (data not shown).
As shown in Fig 4B, (IO pg/mL) inhibited proliferation of normal BCP (fetal CDlO'sIg-cells) cocultured with stromal cells, either in the presence of L 7 (45% inhibition) or in the absence of exogenously added L 7 (58% inhibition; Fig 5B) . Finally, resting peripheral blood T cells proliferated in response to IL-2, IL-4 or IL-7 and a potentiating effect was observed with the combination of IL-2 and IL-7. The addition of MoAb R34.34 (10 pg/mL) to the cultures specifically inhibited IL-7-dependent proliferation, but IL-2-and IL-4-dependent growth was not affected (Fig 5C) . These data indicate that MoAb R34.34 inhibits, but does not totally abrogate, the proliferative effects of IL-7 on both B-and T-lineage cells.
MoAb R34.34 inhibits binding of IL-7 to CDw127. Because MoAb R34.34 was shown to modulate the biologic effects of IL-7, we investigated the mechanism by which the antibody interferes with IL-7 function. Because R34.34 is directed against the CDw l27 IL-7R, it follows that the antibody is likely to either interfere with IL-7 binding or induce a conformational change in CDw127 that would prevent signal transduction of IL-7 bound to its receptor. To answer this question, IL-7 binding experiments were performed in the presence of increasing concentrations of MoAb R34.34. As shown in Fig 6, R34 .34 antibody was shown to inhibit the specific binding of IL-7 to Pre-Alp cells in a dose-dependent fashion, with an estimated 50% effect at 3.8 pg/mL MoAb R34.34. However, the antibody did not totally abrogate IL-7 binding, even at an MoAb R34.34 concentration as high as 25 yglmL (Fig 6) .
These data indicate that MoAb R34.34 recognizes an epitope either within or close to the binding site of IL-7 to CDw127 and that the biologic activity of the antibody results from interference with IL-7 binding.
DISCUSSION
In the present study, MoAbs were raised against a preAlp, pre-B-ALL cell line as a strategy to characterize novel molecules involved in the regulation of human B-cell ontogeny. In this context, four antibodies inhibiting stromal celldependent proliferation of fetal BCP were selected. Among them, MoAb R34.34 was the more potent and, thus, was chosen for further analysis.
The biologic effects of the antibody on BCP and its reactivity pattern on various cell types suggested that R34.34 antigen could be an IL-7 R. Furthermore, the molecular mass of R34.34 antigen as evaluated by immunoprecipitation was around 80 k D , which is close to the 75 to 80 kD described for the CDw127 IL-7R.I5 Finally, MoAb R34.34 was found to inhibit IL-7 binding to Pre-Alp cells. To exclude the possibility that MoAb R34.34 recognized another molecule involved in IL-7 signal transduction;formal identification was performed by expression cloning of cDNA encoding R34.34 antigen. Sequencing data showed that R34.34 antibody recognizes CDw127, the IL-7R described by Goodwin et al.I5 However, three mutations were found at the nucleotide level, although only one modified the amino acid sequence. The change from Val into Ile, localized in the intracytoplasmic domain of the IL-7R of Pre-Alp cells, is probably minor because the two amino acids have close physiochemical properties. This modification may correspond to allelic variations as reported ea~1ier.I~ Reactivity of R34.34 antibody as measured by flow cytometry showed that BCP, peripheral T cells, and some monocytes expressed CDw127, whereas mature B cells did not, which is in agreement with previous descriptions using binding techniques with IL-7.I9 Only cells from some BCP-ALL cases reacted with R34.34 (data not shown), and it will be of interest to correlate this feature with IL-7 responsiveness. A subset of normal CDlO+sIg-BCP lacked R34.34 expression, which likely reflects sequential acquisition of the CDw127 IL-7R during BCP differentiation, in line with murine data.25 As has been reported on some fresh leukemic BCP cases7 and on the t(4; 11) biphenotypic ALL cell line Bl,' proliferation of the BCP-ALL cell lines, Mieliki and Reh, was inhibited by IL-7. It is of interest that this effect of IL-7 was reverted by R34.34 antibody, implying that CDw127 can also mediate growth inhibition. In this context, the description that this IL-7R is detected by reverse transcriptase-polymerase chain reaction in B 1 cells' may suggest but does not show that it mediates the IL-7 antagonism observed in these cells.
Antibody R34.34 also neutralized the proliferation of normal BCP induced in association with stromal cells in the presence of but also in the absence of exogenous IL-7, confirming previous data on the role of stromal cell-derived IL-7 in normal human BCP de~elopment.~ In addition, proliferative effects of IL-7 were inhibited by MoAb R34.34 on the BCP-ALL cells, Pre-Alp, and on resting peripheral T lymphocytes. Together, these data show that the conformation of CDw127 resulting in interference of MoAb R34.34 with IL-7 effects is not a specific feature of B-lineage cells.
It is noteworthy that MoAb R34.34 did not totally abrogate the biologic effects of IL-7 (either growth-inhibitory or agonistic) on several of the cell types tested. A number of possible reasons may explain these observations. First, factors independent of IL-7 may participate in stimulation of cell proliferation. This is clearly the case for BCP cultured on stromal cells: and our present results with MoAb R34.34 are in accordance with the failure of neutralizing anti-IL-7 antibody to completely abrogate stroma-dependent BCP growth.26 Secondly, IL-7 may exert part of its effects through the alternative low-affinity receptor that has been described." In that situation, MoAb R34.34 would not block all effects of IL-7, because it is specific for the CDw127 receptor. This second possibility would be consistent with the lack of complete inhibition of IL-7 binding on Pre-Alp cells. In this context, it would appear possible that Reh cells lack the alternative IL-7 R, thus explaining our observed capacity of MoAb R34.34 to entirely neutralize IL-7 activity on these cells. A third possibility may be that there exist differences in efficacy of IL-7 bound to its CDw 127 receptor, perhaps related to receptor reserve in different types of cells. In the latter situation, occupancy of small numbers of CDw127 molecules by IL-7 (saturation of all receptors with MoAb R34.34 may not be possible) could result in detectable biologic activity.
Collectively, our data show that both inhibitory and agonistic growth signals of IL-7 can be mediated by the same receptor and that these opposite biologic effects are neutralized by anti-CDwl27 MoAb R34.34, which interferes with IL-7 binding.
Thus, inhibitory effects of IL-7 are not exclusively associated with expression of the second low-affinity IL-7R as could have been speculated from previous data." The mechanism by which the CDw 127 IL-7R can antagonize proliferation remains unknown. It can be proposed that such an effect results from an intracellular messenger different from the p59 fyn tyrosine kinase previously shown to associate with CDw127.'* However, it could also be the consequence of a difference in expression of the IL-2R y-chain that was recently shown to be a functional component of the IL-7R." The presently described R34.34 antibody should be of particular interest for studies of signal transmission through the CDw127 IL-7R on various normal and leukemic hematopoietic cells.
